These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25617259)

  • 1. Acquired hemophilia possibly induced by etanercept in a patient with rheumatoid arthritis.
    Banse C; Benhamou Y; Lequerré T; Le Cam-Duchez V; Lévesque H; Vittecoq O
    Joint Bone Spine; 2015 May; 82(3):200-2. PubMed ID: 25617259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired hemophilia, rheumatoid arthritis, and TNFα antagonists: Comment on the article "Acquired hemophilia possibly induced by etanercept in a patient with rheumatoid arthritis" by Banse et al., Joint Bone Spine 2015;82:200-2.
    Brinster A; Bertrand MA; Guillot X; Sondag M; Wendling D
    Joint Bone Spine; 2015 Oct; 82(5):384-5. PubMed ID: 26027776
    [No Abstract]   [Full Text] [Related]  

  • 3. Acquired hemophilia in the patient suffering from rheumatoid arthritis: case report.
    Drobiecki A; Pasiarski M; Hus I; Sokołowska B; Wątek M
    Blood Coagul Fibrinolysis; 2013 Dec; 24(8):874-80. PubMed ID: 24042266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply to the comment of Brinster et al. "Acquired hemophilia, rheumatoid arthritis, and TNFα antagonists".
    Banse C; Vittecoq O; Lévesque H
    Joint Bone Spine; 2015 Oct; 82(5):385-6. PubMed ID: 26162633
    [No Abstract]   [Full Text] [Related]  

  • 5. Direct Comparative Effectiveness Among 3 Anti-Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis.
    Santos-Moreno P; Sánchez G; Gómez D; Bello-Gualtero J; Castro C
    J Clin Rheumatol; 2016 Mar; 22(2):57-62. PubMed ID: 26886438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cat scratch disease during etanercept therapy in a rheumatoid arthritis patient.
    Orden AO; Nardi NN; Vilaseca AB; Colombini AC; Barrios NG; Vijnovich Barón A
    Reumatol Clin (Engl Ed); 2018; 14(5):303-306. PubMed ID: 28256443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database.
    Lee MY; Shin JY; Park SY; Kim D; Cha HS; Lee EK
    Semin Arthritis Rheum; 2018 Feb; 47(4):485-491. PubMed ID: 28939234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry.
    Cárdenas M; de la Fuente S; Font P; Castro-Villegas M; Romero-Gómez M; Ruiz-Vílchez D; Calvo-Gutiérez J; Escudero-Contreras A; Casado M; Del Prado J; Collantes-Estévez E
    Rheumatol Int; 2016 Feb; 36(2):231-41. PubMed ID: 26494567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained response to rituximab in a TNFi-induced ANCA-vasculitis developed in a patient with rheumatoid arthritis.
    Florez H; Morlà R; Castellanos-Moreira R; Sanmartí R
    Semin Arthritis Rheum; 2018 Feb; 47(4):e15-e16. PubMed ID: 29150206
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting Acquired Hemophilia A with Rheumatoid Arthritis by a Rituximab Shot: A Case Report and Review of the Literature.
    Ghozlani I; Mounach A; Ghazi M; Kherrab A; Niamane R
    Am J Case Rep; 2018 May; 19():582-588. PubMed ID: 29780157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
    García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
    Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.
    Geborek P; Crnkic M; Petersson IF; Saxne T;
    Ann Rheum Dis; 2002 Sep; 61(9):793-8. PubMed ID: 12176803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
    J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients.
    Verschueren K; Van Essche E; Verschueren P; Taelman V; Westhovens R
    Clin Rheumatol; 2007 Nov; 26(11):1969-71. PubMed ID: 17340045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of etanercept, infliximab and methotrexate in the treatment of arthritis.
    Wang L; Liu Y; Su X; Liu S
    Drug Res (Stuttg); 2015 Feb; 65(2):96-100. PubMed ID: 25050521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.
    l'Ami MJ; Kneepkens EL; Nurmohamed MT; Krieckaert CLM; Visman IM; Wolbink GJ
    Clin Exp Rheumatol; 2017; 35(3):431-437. PubMed ID: 28079512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
    Soubrier M; Pereira B; Frayssac T; Fan A; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
    Int J Rheum Dis; 2018 Nov; 21(11):1924-1932. PubMed ID: 28901727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful rituximab therapy of acquired factor VIII inhibitor in a patient with rheumatoid arthritis.
    Oliveira B; Arkfeld DG; Weitz IC; Shinada S; Ehresmann G
    J Clin Rheumatol; 2007 Apr; 13(2):89-91. PubMed ID: 17414538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.